N/A N=49 Bilateral Dispensing Study of MyDay Toric, 1-day Acuvue Moist for Astigmatism, and Dailies Aquacomfort Plus Toric Lenses
Astigmatism
Primary: Comfort — 8; 9; 8 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=2,684 A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care
Osteoporosis
Primary: Number of Participants That Initiate an Osteoporosis Prescription Medication — 157; 153 Participants
Phase 2 N=136 Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide
Nausea · Vomiting · Glioma
Primary: Proportion of Patients Achieving Complete Control (CC) — 0.59; 0.55 proportion of patients
Phase 3 N=624 Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
Acute Leukemias of Ambiguous Lineage · Bacterial Infection · Diarrhea
Primary: Comparison of the Percentage of Patients Having Bacteremia Incidence Between Levofloxacin vs. No Prophylaxis Arms — 21.9; 43.4; 11; 17.3 Percentage of patients
Phase 2 N=92 Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Multiple Myeloma
Primary: The Clinical Benefit Response (CBR) — 1; 1; 0; 12 Participants
Phase 2 N=305 Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents
Meningococcal Disease
Primary: Percentage of Subjects Without Bactericidal Activity at 1:4 Dilution Against Each US Neisseria Meningitidis (N. Meningitidis) Serogroup B Strain at One Month After the…
N/A N=242 VenaSeal Sapheon Closure System Pivotal Study (VeClose)
Great Saphenous Vein (GSV) With Venous Reflux Disease
Primary: Number of Participants With Complete Closure of the Target Vein at 3 Months — 107; 109 Participants — p=<0.0001
Phase 4 N=97 Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler Devices
Pulmonary Disease, Chronic Obstructive (COPD)
Primary: Peak Inspiratory Flows Rates Summary by Inhalation Devices - PPS — 107.52; 80.73; 53.59 L/min — p=<0.0001
Phase 3 N=298 Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
Prostate Cancer
Primary: Number of Participants With Progression-Free Survival — 66; 84 Participants — p=0.40
Phase 3 N=300 Vitamin D and Breast Cancer Biomarkers in Female Patients
Breast Cancer
Primary: Percent Change (Between Baseline and Month 12) in Mammographic Density by the Boyd Method Compared Between Arms — -3.4; -1.4 percent change
Phase 4 N=162 A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients
Heart Transplantation
Primary: Calculated Glomerular Filtration Rate (cGFR) Using Modification of Diet in Renal Disease (MDRD) Formula at Month 18 — 54.2; 66.9 mL/min — p=<.0001
Phase 2 N=70 C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
End Stage Renal Disease · Kidney Failure · Delayed Graft Function
Primary: Number of Patients Enrolled With Serum Creatinine >3mg/dL on Postoperative Day 5. — 29; 32 Participants
N/A N=40 Pain Relief at Iliac Crest Bone Harvest Sites in Spine Surgery Using Bupivacaine
Pain
Primary: Pain, Cumulative Visual Analog Score, 1st Follow Up — 10.5; 21.7 units on a scale
Phase 4 N=20 The Effect of Silver Diamine Fluoride (SDF) on Bacteria Involved in Root or Cervical Carious Lesions
Caries
Primary: Change in Bacterial Composition Before and One Month After SDF Application to Root or Cervical Caries Lesions — 1890087; 1959306 bacterial count
N/A N=608 Enhancing Health Care Access With Cellular Technology
Vaccination
Primary: Immunization Rate — 41.7; 40.1; 50.0 Percentage of immunizations